Proteome Regulatory News (PRM)

24 April 2018

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Board Appointment

Proteome Sciences (AIM: PRM) is pleased to announce that Mr Richard Dennis has today been appointed to the Board of Directors. As communicated on 3 April 2017, when he joined the Company as its first Chief Commercial Officer, Mr Dennis has over 30 years' experience in the sector gained most recently as Director of International Commercial Operations at Quanterix Corp, and prior to that in positions of increasing responsibility at Bioscale Inc. and Meso Scale Discovery.

Commenting on this appointment, Jeremy Haigh, Chief Executive Officer, said: "I am delighted to welcome Richard to the Board. Since joining a year ago Richard has transformed our commercial identity and ambition with his focus on face to face selling, account management, and an established client network across Europe. His arrival heralded a relaunch of our services business and inspired a complete review of our commercial practice resulting in the adoption of an agent-based sales model in our principal operating territories. His deep experience of strategic sales and marketing within the bioscience sector will be an asset to the Board at this critical juncture in the Company's development"

For further information:

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant®) and for the discovery, validation and assay development of protein biomarkers (TMTcalibrator™). The company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services™ division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.

Proteome Sciences has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.

Additional information on Mr Richard Paul Dennis (aged 59)

The following additional information is provided in accordance with Schedule 2(g) of the AIM Rules for Companies:

Current and past Directorships:

Mr Dennis currently holds 0 Ordinary Shares of 1p each in the capital of the Company ("Ordinary Shares") and 3,250,000 options over Ordinary Shares of 1p each.

There are no further disclosures required under Schedule 2(g) of the AIM Rules for Companies.

This announcement contains inside information for the purpose of Article 7 of EU Regulation 596/2014